Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer

Abstract Background Stereotactic ablative body radiotherapy (SABR) is an emerging treatment for patients with primary renal cell carcinoma (RCC). However, its impact on renal function is unclear. This study aimed to evaluate incidence and clinical factors predictive of severe to end-stage chronic ki...

Cijeli opis

Bibliografski detalji

Glavni autori:	Muhammad Ali, Kendrick Koo, David Chang, Phil Chan, Sheng F. Oon, Daniel Moon, Declan G. Murphy, Renu Eapen, Jeremy Goad, Nathan Lawrentschuk, Arun A. Azad, Sarat Chander, Mark Shaw, Nicholas Hardcastle, Shankar Siva
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2024-02-01
Serija:	Radiation Oncology
Teme:	Stereotactic ablative radiotherapy SABR Renal cell carcinoma RCC Chronic kidney disease End-stage renal disease
Online pristup:	https://doi.org/10.1186/s13014-024-02413-w
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!